I recently bought in @ $48. and read this latest report:
Given its well-balanced, diversified portfolio and decent balance sheet, not to mention the strategic acquisitions and tie-ups, we believe that HCP remains well poised to capitalize on the promising prospects in the industry and benefit its shareholders accordingly.
I'm in it for the long haul.
I'm a new comer to CEF's.
are the distributions $0.10 monthly?
Also since it not considered a "dividend", will I receive a 1099 tax form or a K1 ?
I have Fidelity as my broker.
The spec. sheet says distributions = $0.10 / share monthly.
Which is correct? $0.78 or $1.20
Today from SA:
•PAA’s sustainable cash flow in 2014 did not materially differ from reported DCF due to a number of offsetting items.
•PAA is not financing its distributions via issuance of new units or debt.
•The drop in the 2014 coverage ratio from the prior-year level was expected.
•Revised guidance lowers not only the rate of distribution growth but also implies no excess coverage in 2015; this could significantly increase in PAA’s risk profile.
Why the thumbs down, I didn't write the article, only reported it.
I own a considerable amount of PAA and with hold on for the ride!!
Sentiment: Strong Buy
I read it and believe it will be an "Option", similar to DRIP's.
Rather than pay cash, they'll pay out in shares of stock
AbbVie is spending $21 billion to acquire Pharmacyclics, which works out to $261.25 per share. But AbbVie is only buying half of Imbruvica because Johnson & Johnson (JNJ) already gets 50% of the drug's revenue. J&J acquired its interest in Imbruvica via a partnership signed with Pharmacyclics before the the drug was approved.
Both boards have signed off on AbbVie's (NYSE:ABBV) $21B surprise acquisition of Pharmacyclics (NASDAQ:PCYC), announced a short while ago amid speculation that Johnson & Johnson (NYSE:JNJ) (or, earlier, Novartis (NYSE:NVS)) would be the one to acquire the cancer biotech.
With the deal, AbbVie gets Pharmacyclics' blockbuster Imbruvica drug for hematologic malignancies -- which logged $548M in revenues in 2014 (Q4 earnings) and might go all the way to $5B/year. Imbruvica has received four indications in less than 15 months -- the latest being for Waldenström's Macroglobulinemia at the end of January.
I agree with your assessment.
Furthermore, why pay a $30 premium over the asking price?
I can't believe this was approved entirely by the board.
What about partner JNJ?
Remember what you just said at voting time.
People who make bad decisions lose their jobs.
This was a very bad decision and the board will pay.
•ABBV's acquisition of PCYC will create shareholder value in itself.
•ABBV investors have completely ignored this stock driving catalyst and the launch of Viekira Pak due to the fear of Humira facing biosimilars.
•However, AbbVie's CEO is confident that Humira will keep patent protection until the 2030s, meaning ABBV is now one of the cheapest big biotechs in the industry.
Not sure if I like it or not, what I don't like is I bought in @ $65
Will hold the course for now and hope for the best.
I agree with your assessment and did exactly what you did, but bought in at $65.
I'm not sure if the acquisition was a good deal. Appears they paid a Premium for it.
Good or bad I shall hold the course.
Nothing is certain, only death.
Although I own COP and many other oil equities, I would avoid all oils for now.
Too much uncertainness.
However if you can sleep at night w/o thinking about your equities it would be a good time to get your feet wet.
I wouldn't buy a stock just for the dividends...do some research.